Axsome Therapeutics, Inc. (AXSM): Price and Financial Metrics


Axsome Therapeutics, Inc. (AXSM): $29.72

1.19 (+4.17%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

AXSM Stock Price Chart Interactive Chart >

Price chart for AXSM

AXSM Price/Volume Stats

Current price $29.72 52-week high $87.24
Prev. close $28.53 52-week low $19.38
Day low $27.80 Volume 1,354,900
Day high $29.79 Avg. volume 659,456
50-day MA $37.47 Dividend yield N/A
200-day MA $59.86 Market Cap 1.12B

Axsome Therapeutics, Inc. (AXSM) Company Bio


Axsome Therapeutics Inc. focuses on developing therapies for the management of pain, neurological disorders, and other central nervous system. The company was founded in 2012 and is based in New York City, New York.


AXSM Latest News Stream


Event/Time News Detail
Loading, please wait...

AXSM Latest Social Stream


Loading social stream, please wait...

View Full AXSM Social Stream

Latest AXSM News From Around the Web

Below are the latest news stories about Axsome Therapeutics Inc that investors may wish to consider to help them evaluate AXSM as an investment opportunity.

Axsome (AXSM) Begins Late-Stage Sleep Disorder Study on AXS-12

Axsome (AXSM) is developing AXS-12 as a potential treatment for narcolepsy. The company initiates enrollment in a phase III study evaluating AXS-12.

Yahoo | September 17, 2021

Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial of AXS-12 in Narcolepsy

NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, enrolled the first patient in SYMPHONY (Study Evaluating a Mechanistic Approach to Treating Narcolepsy), a Phase 3, randomized, double-blind, placebo-controlled trial of AXS-12 in patients with narcolepsy. AXS-12 is a novel, oral, potent, and highly selective norepinephrine reuptake inhibitor. T

Yahoo | September 16, 2021

Axsome's (AXSM) Migraine Drug AXS-07 NDA Gets FDA Acceptance

Axsome (AXSM) is seeking approval for its key pipeline candidate, AXS-07, as a potential acute treatment for migraine.

Yahoo | September 15, 2021

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-07 for the Acute Treatment of Migraine

NEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s New Drug Application (NDA) for AXS-07 for the acute treatment of migraine, and has set a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2022 for the NDA. AXS-07 (MoSEIC™

Yahoo | September 14, 2021

Axsome Therapeutics Inc Ranked Among Todays Top Shorts After The European Central Bank Says It May Slow Down Bond Purchases

The post Axsome Therapeutics Inc Ranked Among Todays Top Shorts After The European Central Bank Says It May Slow Down Bond Purchases appeared on BitcoinEthereumNews.com . Getty For the second week in a row, we hit a pandemic-era low in jobless claims. This is a very welcome positive signal for the market and the labor situation.

Bitcoin Ethereum News | September 9, 2021

Read More 'AXSM' Stories Here

AXSM Price Returns

1-mo 37.85%
3-mo -58.23%
6-mo -49.14%
1-year -63.60%
3-year 814.46%
5-year 284.48%
YTD -63.52%
2020 -21.18%
2019 3,565.25%
2018 -49.64%
2017 -17.04%
2016 -27.18%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8642 seconds.